Skip to main content


You are here


UM Ventures has seen strong increases in technology transfer results.

5-year growth:

  • License Agreements: 100% 
  • StartUps Based on UM IP: 80%
  • Disclosures: 61% 
University of Maryland, College Park UMCP
2011 2012 2013 2014 2015 2016 
Invention Disclosures 118 134 136 196  167  195
Start-ups (additional info)
2 4 8 5  5  10
Licenses 14 13 18 21  16  22
University of Maryland, Baltimore UMB 2011 2012 2013 2014  2015 2016
Invention Disclosures 88 131 128 170  139  136
Start-ups (additional info)
3 3 3 3  5  10
Licenses 14 21 23 30  39  34
Total 2011 2012 2013 2014  2015 2016
Invention Disclosures 206 265 264 366  306  331
Start-ups (additional info)
5 7 11 8  10  20
Licenses 28 34 41 51  55  56

A sampling of recent UM Ventures licensees successes includes:

  • Alba Therapeutics licensed its UMB-invented therapeutic to treat celiac disease to Innovate Biopharmaceuticals.  Innovate plans to start Phase 3 clinical trials in 2016.
  • Analytical Informatics (AI) signed a global marketing agreement whereby Toshiba is marketing AI's products.
  • FlexEl, a custom battery solutions company, opened new 10,000-square-feet of design and manufacturing space in College Park. FlexEl will add 50 jobs within five years.
  • GripBoost is on pace to sell 30,000 bottles of its Grip Boost Football Gel in 2016.  A UMCP start-up, GripBoost has won $200,000 in TEDCO grants and $250,000 from the VOLT fund.
  • Harpoon Medical is commercializing a surgical device for beating heart mitral valve repair.  Harpoon raised a $6 million Series A round in late 2014, which funded clinical trials in Europe.  Based on the success of these trials, Harpoon raised a second round of funding in December 2015 that is "magnitudes larger."  The most recent financing was ed by Edwards Lifesciences Corp, which has an option to acquire Harpoon.
  • Mtech is teaming with IBBR to manage and launch start-up companies affiliated with IBBR-based faculty.
  • N5 Sensors, a UMCP start-up commercializing chip-based chemical sensor technology, won multiple SBIR, MII, and MIPS grants totaling $1.6 million and a $500,000 contract with NIST.
  • OmniSpeech, a UMCP software start-up commercializing a technology to enhance voice communication raised $2 million in 2016.
  • PaxVax is a vaccine-development company with multiple technologies in its pipeline.  One of its two-leading technologies is a travelers' cholera vaccine owned by UMB that has been approved by the U.S. Food & Drug Administration.  PaxVax has raised over $200 million.
  • Profectus Biosciences has raised over $100 million in equity and grant funding to support developing vaccines for HIV/AIDS, Ebola, and encephalitis.  Its vaccine for HIV/AIDS is in clinical trials.
  • Remedium, a joint UMCP/UMB company, received FDA approval in 2015 for a device that stops severe bleeding instantly.  Two additional devices are in the pipeline.
  • Remedy Pharmaceuticals announced positive Phase 2 clinical trial results of its drug candidate to treat stroke and launched a national multi-center trial to treat spinal cord injuries.  In December 2015, Remedy announced that it had completed a $9 million round of financing that includes investments from The Vertical Group.  It is commencing Phase 3 clinical trials in 2016.
  • Tokai Pharmaceuticals is conducting Phase 3 clinical trials on a drug candidate to treat prostate cancer.  It is in negotiations to license additional technologies from UMB.
  • VisiSonics licensed its technology for 3D sound to Oculus, a company co-founded by Brendan Iribe (UMCP 1993).  The VisiSonics technology is a critical component of the Oculus Rift, which began sales in March. VisiSonics has also licensed the technology to Tesla and SpaceEx.
  • Xcision has developed a specialized radiation therapy device to treat breast cancer.  It is currently installed in five medical centers and the first patient was treated under a clinical trial on March 18, 2016.  FDA approval is expected by the end of 2016.